Cannabinoid drugs could be used therapeutically. A major drawback hampering their clinical application is their capacity to induce psychotic-like symptoms.
Type-1 cannabinoid receptors (CB1) are located throughout the body and mediate central processes including appetite, mood and memory. Cannabinoid drugs bind to and activate CB1 receptors. Emerging evidence indicates the involvement of both mitochondrial and astrocyte CB1 receptors in psychotic-like conditions, although molecular and cellular insight into the mechanism is currently lacking.
Further details: Mechanistic insight into cannabinoid drug-induced psychosis